Travere Therapeutics' Filspari boosts revenue with FDA approval, but heavy losses and competitive threats raise concerns for 2025. Click to read why TVTX is a Hold.

The two-year results from the study were published in the New England Journal of Medicine and showed that sparsentan delivered clinically meaningful benefit at 108 weeks with significant ...

seeking priority review for traditional approval of FILSPARI ® (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS). The submission is supported by results from the Phase 3 ...

The two-year results from the study were published in the New England Journal of Medicine and showed that sparsentan delivered clinically meaningful benefit at 108 weeks with significant proteinuria ...

It might become a family affair in East Lansing. On Thursday, On3 reported that four-star athlete Salesi Moa set an early official visit with Michigan State for the weekend of April 2. Moa's ...

In 1934, the NZ Herald reported on moa remains discovered in a swamp on a Canterbury farm. Photo / Mark Mitchell Kem Ormond takes a look at the world of farming back in the day. Moa were large ...

Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI® (sparsentan) for FSGS Net product sales of FILSPARI totaled $50 million in 4Q 2024; $132 million for ...

Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [ID6369] Draft guidance Technology appraisal guidance 2 April ...

Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EMA’s human medicines ...